Cholesterol Metabolites Analysis in Human Thyroid and Iodine Resistance

Completed

• Conditions: Thyroid Cancer
• Interventions: Other: Metabolites dosage

• Registration Number: NCT04821336
• Lead Sponsor: Institut Claudius Regaud

Brief Summary

The study team previously shown that a cholesterol metabolite, dendrogenin A (DDA) differentiates anaplastic thyroid cancer cell lines and that its mRNA expression is diminished in human radioiodine refractory thyroid cancer samples. The team aim to quantify via mass spectrometry and immunohistochemistry DDA and other cholesterol metabolites in thyroid cancer versus healthy thyroid tissue human samples.

Detailed Description

Retrospective study to analyze tissue samples of patients after thyroid surgery at Claudius Regaud Institute Toulouse, France, for thyroid cancer or thyroid aggressive lymphoma or benign thyroid pathology or other head\&neck pathology necessitating total thyroidectomy despite normal thyroid.

Analysis focused on cholesterol metabolites quatification by mass spectrometry in liquid and gas phase.

Study Timeline

• Study First Submitted: 2021-03-25
• Study First Submitted QC: 2021-03-25
• Study First Posted: 2021-03-29
• Study Start: 2021-04-15
• Primary Completion: 2022-09-30
• Status Verified: 2022-12
• Study Completion: 2022-12-31
• Last Update Submitted: 2023-04-28
• Last Update Posted: 2023-05-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Patients who have undergone surgery at Institut Claudius Regaud for thyroid or laryngeal cancer confirmed by histology.
• Patients who have consented before surgery, for the use of participants samples for future researches.

Read More

Exclusion Criteria

• None

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Thyroid tissue samples	Metabolites dosage	from 30 patients, tissue samples , frozen and embedded paraffin have been collected and preserved for research. For this study, tumoral tissue and healthy tissue will be used;

Primary Outcome Measures

Name	Time	Method
Rate of dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) in thyroid tissue (healthy or malignant)	12 months after the beginning of the study	The measurement expressed in ng / g of thyroid tissue

Secondary Outcome Measures

Name	Time	Method
Presence of enzymes involved in dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) production	12 months after the beginning of the study	intensity of signal in Liquid Chromatography-Mass Spectrometry
Number of enzymes involved in denrognenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) production	12 months after the beginning of the study	Quantify by immunohistochemistry

Trial Locations

Locations (1)

Institut Claudius regaud IUCT Oncopole; 🇫🇷 Toulouse, France